Cochlear |
High $229.15 |
Low $226.18 |
Trades 9,945 |
Turnover $41,610,921 |
Volume 181,871 |
| 30 June 2023 at 4:12pm | ||||
|
Market Cap (16-Nov) $9,899,433,984 (45th) |
Close (30-Jun) $229.07 |
Volume (30-Jun) 181,871 |
Shortsold (9-Nov) 647,255 (0.99%) (266th) |
|
52w High $278.60 |
52w Low $87.88 |
P/E 29.67 |
EPS 2.25 |
[ARTICLE] Can a vaccine slow down the Cochlear train?
A news article has been posted about Cochlear on the AFR. The article was published around , on 28 March 2024 at 11:40am.
Nasdaq-listed Moderna is trialling a potential vaccine against Cytomegalovirus (CMV), which is the most common infectious cause of birth defects in the United States and can cause newborn hearing loss. It is in phase 3 trials and Moderna said this week it should have results later this year.
Read ArticleCOH was $229.07 at the close of trade on 30 June 2023
| Recent Articles about ASX:COH | |
|---|---|
| 12-Jun | ASX falls, BHP down; Cettire dives 31pc
afr.com |
| 30-May | Labor takes $27m stake in breakthrough eye biotech
afr.com |
| 14-Apr | ‘Could be next Cochlear or ResMed’: heart device maker wins FDA approval
afr.com |
| 14-Feb | Cochlear says US cost-of-living pressures hit services revenue
afr.com |
| 31-Dec | David Kent Honoured For Services To Deaf And Hard Of Hearing Community
scoop.co.nz |
| 30-Dec | Whitehall and officer accused in death of man with disabilities respond to allegations
msn.com |
| 30-Dec | Sensorion completes enrollment of the first cohort of the Audiogene phase 1/2 gene therapy clinical trial
pharmabiz.com |
| 30-Dec | 3D printed microneedles used to treat hearing loss
voxelmatters.com |
| 29-Dec | Mumbai: KEM Hospital's Cochlear Implant Programme Transforms Lives Of 650 Hearing-Impaired Children
msn.com |
| 28-Dec | Iowans are 'Hearing' again thanks to the UIHC Cochlear Implant Program and decades of research
kwwl.com |
| Tracked |
Find all articles about Cochlear, including others on the AFR, on the media page.
If you were already registered, log in here.